143 related articles for article (PubMed ID: 36154893)
1. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice.
Wang H; Zhang J; Zhang X; Zhao N; Zhou Z; Tao L; Fu L; Peng S; Chai J
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166556. PubMed ID: 36154893
[TBL] [Abstract][Full Text] [Related]
2. Astragalus saponins protect against extrahepatic and intrahepatic cholestatic liver fibrosis models by activation of farnesoid X receptor.
Zhang L; Shi J; Shen Q; Fu Y; Qi S; Wu J; Chen J; Zhang H; Mu Y; Chen G; Liu P; Liu W
J Ethnopharmacol; 2024 Jan; 318(Pt A):116833. PubMed ID: 37400008
[TBL] [Abstract][Full Text] [Related]
3. Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF-κB pathway.
Tu S; Jiang Y; Cheng H; Yuan X; He Y; Peng Y; Peng X; Peng Z; Tao L; Yang H
FASEB J; 2021 Jul; 35(7):e21497. PubMed ID: 34152015
[TBL] [Abstract][Full Text] [Related]
4. Fluorofenidone attenuates hepatic fibrosis by suppressing the proliferation and activation of hepatic stellate cells.
Peng Y; Yang H; Wang N; Ouyang Y; Yi Y; Liao L; Shen H; Hu G; Wang Z; Tao L
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(3):G253-63. PubMed ID: 24337009
[TBL] [Abstract][Full Text] [Related]
5. Fluorofenidone alleviates liver fibrosis by inhibiting hepatic stellate cell autophagy
Peng X; Yang H; Tao L; Xiao J; Zeng Y; Shen Y; Yu X; Zhu F; Qin J
PeerJ; 2023; 11():e16060. PubMed ID: 37790613
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol suppresses cholestasis-induced liver injury and fibrosis in rats associated with the inhibition of TGFβ1-Smad3-miR21 axis and profibrogenic and hepatic injury biomarkers.
ShamsEldeen AM; Al-Ani B; Ebrahim HA; Rashed L; Badr AM; Attia A; Farag AM; Kamar SS; Haidara MA; Al Humayed S; Ali Eshra M
Clin Exp Pharmacol Physiol; 2021 Oct; 48(10):1402-1411. PubMed ID: 34157155
[TBL] [Abstract][Full Text] [Related]
7. Fluorofenidone protects against acute liver failure in mice by regulating MKK4/JNK pathway.
Gu L; He X; Zhang Y; Li S; Tang J; Ma R; Yang X; Huang H; Peng Y; Xie Y; Peng Z; Meng J; Hu G; Tao L; Liu X; Yang H
Biomed Pharmacother; 2023 Aug; 164():114844. PubMed ID: 37224750
[TBL] [Abstract][Full Text] [Related]
8. Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targeting the TGF-β1/Smad and MAPK signaling pathways.
Peng Y; Li L; Zhang X; Xie M; Yang C; Tu S; Shen H; Hu G; Tao L; Yang H
Exp Ther Med; 2019 Jul; 18(1):41-48. PubMed ID: 31258636
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
10. Lignans from Schisandra sphenanthera protect against lithocholic acid-induced cholestasis by pregnane X receptor activation in mice.
Fan S; Liu C; Jiang Y; Gao Y; Chen Y; Fu K; Yao X; Huang M; Bi H
J Ethnopharmacol; 2019 Dec; 245():112103. PubMed ID: 31336134
[TBL] [Abstract][Full Text] [Related]
11. Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy.
Liao X; Jiang Y; Dai Q; Yu Y; Zhang Y; Hu G; Meng J; Xie Y; Peng Z; Tao L
Biochem Biophys Res Commun; 2021 Jan; 534():694-701. PubMed ID: 33220928
[TBL] [Abstract][Full Text] [Related]
12. The antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways.
Peng Y; Yang H; Zhu T; Zhao M; Deng Y; Liu B; Shen H; Hu G; Wang Z; Tao L
Eur J Clin Invest; 2013 Apr; 43(4):358-68. PubMed ID: 23438945
[TBL] [Abstract][Full Text] [Related]
13. Fluorofenidone inhibits macrophage IL-1β production by suppressing inflammasome activity.
Lu M; Yang W; Peng Z; Zhang J; Mei W; Liu C; Tang J; Ma H; Yuan X; Meng J; Lv B; Liu J; Hu G; Tao L
Int Immunopharmacol; 2015 Jul; 27(1):148-53. PubMed ID: 25983199
[TBL] [Abstract][Full Text] [Related]
14. Fluorofenidone attenuates inflammation by inhibiting the NF-кB pathway.
Huang L; Zhang F; Tang Y; Qin J; Peng Y; Wu L; Wang F; Yuan Q; Peng Z; Liu J; Meng J; Tao L
Am J Med Sci; 2014 Jul; 348(1):75-80. PubMed ID: 24534785
[TBL] [Abstract][Full Text] [Related]
15. Melatonin improves cholestatic liver disease via the gut-liver axis.
Liu X; Li J; Shi M; Fu J; Wang Y; Kang W; Liu J; Zhu F; Huang K; Chen X; Liu Y
J Pineal Res; 2024 Jan; 76(1):e12929. PubMed ID: 38047407
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice.
Li WK; Wang GF; Wang TM; Li YY; Li YF; Lu XY; Wang YH; Zhang H; Liu P; Wu JS; Ma YM
Phytomedicine; 2019 Sep; 62():152948. PubMed ID: 31129431
[TBL] [Abstract][Full Text] [Related]
17. Trillin Reduces Liver Chronic Inflammation and Fibrosis in Carbon Tetrachloride (CCl4) Induced Liver Injury in Mice.
Tan H; He Q; Li R; Lei F; Lei X
Immunol Invest; 2016 Jul; 45(5):371-82. PubMed ID: 27219527
[TBL] [Abstract][Full Text] [Related]
18. D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress.
Zhao SS; Li NR; Zhao WL; Liu H; Ge MX; Zhang YX; Zhao LY; You XF; He HW; Shao RG
Acta Pharmacol Sin; 2018 Feb; 39(2):213-221. PubMed ID: 28748913
[TBL] [Abstract][Full Text] [Related]
19. Danning tablets attenuates α-naphthylisothiocyanate-induced cholestasis by modulating the expression of transporters and metabolic enzymes.
Ding L; Zhang B; Zhan C; Yang L; Wang Z
BMC Complement Altern Med; 2014 Jul; 14():249. PubMed ID: 25033983
[TBL] [Abstract][Full Text] [Related]
20. Paeoniflorin ameliorates ANIT-induced cholestasis by activating Nrf2 through an PI3K/Akt-dependent pathway in rats.
Chen Z; Ma X; Zhu Y; Zhao Y; Wang J; Li R; Chen C; Wei S; Jiao W; Zhang Y; Li J; Wang L; Wang R; Liu H; Shen H; Xiao X
Phytother Res; 2015 Nov; 29(11):1768-75. PubMed ID: 26269092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
